Drug Trial Radar · NCT02207244
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
Last checked: Nov 20, 2026Latest source record: Jul 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
992
Actual
Start
Nov 3, 2014
Primary completion
Oct 1, 2015
Study completion Jul 1, 2020
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Aug 4, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis (scaly skin rash).
Conditions
- Psoriasis
Interventions
Guselkumab 100 mgDrug
100 mg by subcutaneous injection at Weeks 0, 4, 12, and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon randomized treatment group and PASI response (Group I). 100 mg by subcutaneous injection at Weeks 16 and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon PASI response (Group II). Starting at Week 28, participants will receive guselkumab 100 mg through Week 72 depending upon PASI response (Group III). All participants will receive guselkumab q8w starting at Week 76 through Week 252.
Placebo for guselkumabDrug
Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending on randomized treatment group and PASI response (Group I), at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response (Group II), at weeks 0, 4, 12, 16, and 20, starting at week 28 through week 72 depending upon PASI response (Group III).
AdalimumabDrug
80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 23.
Placebo for adalimumabDrug
Placebo for adalimumab \[two 0.8 milliliter (mL) injections\] at week 0 followed by one 0.8 mL injection at weeks 1, 3, 5, and every 2 week (q2w) through Week 23 (Group I and II).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) in the Guselkumab Group Compared to the Placebo Group at Week 16Time frame: Week 16
- Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response in the Guselkumab Group Compared to the Placebo Group at Week 16Time frame: Week 16
Locations
93 sites in 9 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Bakersfield, California
Site not named
Los Angeles, California
Site not named
San Diego, California
Site not named
Santa Monica, California
Site not named
Aurora, Colorado
Site not named
Coral Gables, Florida
Site not named
Tampa, Florida
Site not named
Newnan, Georgia
Site not named
Sandy Springs, Georgia
Site not named
Chicago, Illinois
Site not named
Rolling Meadows, Illinois
Site not named
Skokie, Illinois
Site not named
Indianapolis, Indiana
Site not named
Plainfield, Indiana
Site not named
Louisville, Kentucky
Site not named
Andover, Massachusetts
Site not named
Fort Gratiot, Michigan
Site not named
Troy, Michigan
Site not named
St Louis, Missouri
Site not named
Albuquerque, New Mexico
Site not named
New York, New York
Site not named
Gahanna, Ohio
Site not named
Norman, Oklahoma
Site not named
Portland, Oregon
Site not named
Pittsburgh, Pennsylvania
Site not named
Johnston, Rhode Island
Site not named
Arlington, Texas
Site not named
Houston, Texas
Site not named
Salt Lake City, Utah
Site not named
Seattle, Washington
Site not named
Spokane, Washington
Site not named
Benowa, Australia
Site not named
Hectorville, Australia
Site not named
Melbourne, Australia
Site not named
Parkville, Australia
Site not named
Westmead, Australia
Site not named
Woolloongabba, Australia
Site not named
Barrie, Ontario, Canada
Site not named
Hamilton, Ontario, Canada
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.